http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105412153-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0665 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10 |
| filingDate | 2015-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105412153-B |
| titleOfInvention | Application of the excretion body of mescenchymal stem cell secretion in preparation prevention and treatment hepatitis C virus cytotoxic drug |
| abstract | The invention belongs to field of biotechnology, provide application of the excretion body of source for mesenchymal stem cells in preparation prevention and treatment Hepatitis C Virus (HCV) drug.Excretion body of the invention is mainly prepared by the following method: the human mesenchymal stem cell being separately cultured；The collection of conditioned medium；Extraction, concentration and the purifying of excretion body.The present invention passes through Hepatitis C Virus (HCVcc) model, the susceptible target cell Bel7402 Huh7 of HCV for the cell origin established in vitro, is detected to the anti-HCV activity of the excretion body in human mesenchymal stem cell source.Experimental result is shown, the excretion body of people's umbilical cord, marrow and the secretion of derived from peripheral blood mescenchymal stem cell has significant anti-HCV activity, level of the viral RNA in cell can be significantly inhibited, experimental data prompt simultaneously, obviously up-regulation has 4 kinds of microRNAs (Let-7f of antiviral activity to excretion body treated cell, miR-145, miR-199a and miR-221).The present invention provides new source and method for HCV-Ab IgG treatment. |
| priorityDate | 2015-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 253.